Signaling pathways in mitral valve degeneration

Journal of Veterinary Cardiology

Volumn 14, Issue 1, 2012, Pages 7-17

  Orton, E Christopher ^a   Lacerda, Carla M R ^a   MacLea, Holly B ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

Degenerative mitral valve disease; Developmental signaling pathways; Myxomatous pathology; Serotonin; Transforming growth factor

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; BONE MORPHOGENETIC PROTEIN; COLLAGEN FIBER; COLLAGENASE 3; DESMIN; FRIZZLED PROTEIN; GELATINASE A; GELATINASE B; GLYCOSAMINOGLYCAN; INTERSTITIAL COLLAGENASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NOTCH RECEPTOR; PHOSPHOLIPASE C; PROTEOGLYCAN; SEROTONIN; SMAD PROTEIN; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX9; TRANSFORMING GROWTH FACTOR BETA; TRYPTOPHAN HYDROXYLASE; WNT PROTEIN;

AGING; ARTICLE; BIOMECHANICS; BONE DEVELOPMENT; CARCINOID SYNDROME; CELL PROLIFERATION; CHONDROGENESIS; CHORDA TENDINEA; CLINICAL FEATURE; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DOG; EXTRACELLULAR MATRIX; GENETIC ASSOCIATION; HEART ATRIOVENTRICULAR VALVE; HEART MYXOMA; HOMEOSTASIS; HUMAN; HYPERTENSION; INHIBITION KINETICS; MARFAN SYNDROME; MITRAL VALVE DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SEROTONIN BLOOD LEVEL; SEROTONIN METABOLISM; SHEAR STRENGTH; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STRUCTURE ACTIVITY RELATION; TENSILE STRENGTH; VALVULAR HEART DISEASE;

CANIS FAMILIARIS;

EID: 84858450117     PISSN: 17602734     EISSN: 18750834     Source Type: Journal    
DOI: 10.1016/j.jvc.2011.12.001     Document Type: Review

References (88)

1. A. Vahanian, B. Iung, D. Himbert, and P. Nataf Changing demographics of valvular heart disease and impact on surgical and transcatheter valve therapies Int J Cardiovasc Imaging 2011
2. B. Iung, and A. Vahanian Epidemiology of valvular heart disease in the adult Nat Rev Cardiol 8 2011 162 172
3. J.C. Whitney Observations on the effect of age on the severity of heart valve lesions in the dog J Small Anim Pract 15 1974 511 522
4. C. Atkins, J. Bonagura, S. Ettinger, P. Fox, S. Gordon, J. Haggstrom, R. Hamlin, B. Keene, V. Luis-Fuentes, and R. Stepien Guidelines for the diagnosis and treatment of canine chronic valvular heart disease J Vet Intern Med 23 2009 1142 1150
5. S. Disatian, E.J. Ehrhart 3rd, S. Zimmerman, and E.C. Orton Interstitial cells from dogs with naturally occurring myxomatous mitral valve disease undergo phenotype transformation J Heart Valve Dis 17 2008 402 411 discussion 412
6. B.D. King, M.A. Clark, N. Baba, J.W. Kilman, and C.F. Wooley "Myxomatous" mitral valves: collagen dissolution as the primary defect Circulation 66 1982 288 296
7. J.E. Barber, F.K. Kasper, N.B. Ratliff, D.M. Cosgrove, B.P. Griffin, and I. Vesely Mechanical properties of myxomatous mitral valves J Thorac Cardiovasc Surg 122 2001 955 962
8. E. Rabkin, M. Aikawa, J.R. Stone, Y. Fukumoto, P. Libby, and F.J. Schoen Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves Circulation 104 2001 2525 2532
9. J. Lincoln, C.M. Alfieri, and K.E. Yutzey Bmp and fgf regulatory pathways control cell lineage diversification of heart valve precursor cells Dev Biol 292 2006 292 302
10. J. Lincoln, A.W. Lange, and K.E. Yutzey Hearts and bones: shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development Dev Biol 294 2006 292 302
11. M.S. Sacks, W. David Merryman, and D.E. Schmidt On the biomechanics of heart valve function J Biomech 42 2009 1804 1824
12. J.T. Butcher, S. Tressel, T. Johnson, D. Turner, G. Sorescu, H. Jo, and R.M. Nerem Transcriptional profiles of valvular and vascular endothelial cells reveal phenotypic differences: influence of shear stress Arterioscler Thromb Vasc Biol 26 2006 69 77
13. J.T. Butcher, and R.M. Nerem Valvular endothelial cells regulate the phenotype of interstitial cells in co-culture: effects of steady shear stress Tissue Eng 12 2006 905 915
14. J.T. Butcher, A.M. Penrod, A.J. Garcia, and R.M. Nerem Unique morphology and focal adhesion development of valvular endothelial cells in static and fluid flow environments Arterioscler Thromb Vasc Biol 24 2004 1429 1434
15. S. Disatian, C. Lacerda, and E.C. Orton Tryptophan hydroxylase 1 expression is increased in phenotype-altered canine and human degenerative myxomatous mitral valves J Heart Valve Dis 19 2010 71 78
16. A.C. Liu, V.R. Joag, and A.I. Gotlieb The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology Am J Pathol 171 2007 1407 1418
17. M.A. Oyama, and R.J. Levy Insights into serotonin signaling mechanisms associated with canine degenerative mitral valve disease J Vet Intern Med 24 2010 27 36
18. B.I. Gustafsson, O. Hauso, I. Drozdov, M. Kidd, and I.M. Modlin Carcinoid heart disease Int J Cardiol 2008
19. J.W. Arndt, C.A. Reynolds, G.E. Singletary, J.M. Connolly, R.J. Levy, and M.A. Oyama Serum serotonin concentrations in dogs with degenerative mitral valve disease J Vet Intern Med 23 2009 1208 1213
20. B.M. Corcoran, A. Black, H. Anderson, J.D. McEwan, A. French, P. Smith, and C. Devine Identification of surface morphologic changes in the mitral valve leaflets and chordae tendineae of dogs with myxomatous degeneration Am J Vet Res 65 2004 198 206
21. P.D. Stein, C.H. Wang, J.M. Riddle, H.N. Sabbah, D.J. Magilligan Jr., and E.T. Hawkins Scanning electron microscopy of operatively excised severely regurgitant floppy mitral valves Am J Cardiol 64 1989 392 394
22. J.T. Butcher, C.A. Simmons, and J.N. Warnock Mechanobiology of the aortic heart valve J Heart Valve Dis 17 2008 62 73
23. J.P. Singh, J.C. Evans, D. Levy, M.G. Larson, L.A. Freed, D.L. Fuller, B. Lehman, and E.J. Benjamin Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the framingham heart study) Am J Cardiol 83 1999 897 902
24. H. Boudoulas Etiology of valvular heart disease Expert Rev Cardiovasc Ther 1 2003 523 532
25. C. Yosefy, and A. Ben Barak Floppy mitral valve/mitral valve prolapse and genetics J Heart Valve Dis 16 2007 590 595
26. E.H. Stephens, and K.J. Grande-Allen Age-related changes in collagen synthesis and turnover in porcine heart valves J Heart Valve Dis 16 2007 672 682
27. V. Gupta, J.A. Werdenberg, B.D. Lawrence, J.S. Mendez, E.H. Stephens, and K.J. Grande-Allen Reversible secretion of glycosaminoglycans and proteoglycans by cyclically stretched valvular cells in 3d culture Ann Biomed Eng 36 2008 1092 1103
28. C.M.R. Lacerda, H.B. MacLea, J. Kisiday, and E.C. Orton Static and cyclic tensile strain induce myxomatous effector proteins and serotonin in canine mitral valve J Vet Cardiol 2012
29. E.H. Stephens, T.C. Nguyen, A. Itoh, N.B. Ingels Jr., D.C. Miller, and K.J. Grande-Allen The effects of mitral regurgitation alone are sufficient for leaflet remodeling Circulation 118 2008 S243 S249
30. D.J. Walther, J.U. Peter, S. Bashammakh, H. Hortnagl, M. Voits, H. Fink, and M. Bader Synthesis of serotonin by a second tryptophan hydroxylase isoform Science 299 2003 76
31. W. Ni, and S.W. Watts 5-hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (sert) Clin Exp Pharmacol Physiol 33 2006 575 583
32. J. Xu, B. Jian, R. Chu, Z. Lu, Q. Li, J. Dunlop, S. Rosenzweig-Lipson, P. McGonigle, R.J. Levy, and B. Liang Serotonin mechanisms in heart valve disease ii: the 5-ht2 receptor and its signaling pathway in aortic valve interstitial cells Am J Pathol 161 2002 2209 2218
33. J.M. Launay, G. Birraux, D. Bondoux, J. Callebert, D.S. Choi, S. Loric, and L. Maroteaux Ras involvement in signal transduction by the serotonin 5-ht2b receptor J Biol Chem 271 1996 3141 3147
34. Y. Liu, Y.J. Suzuki, R.M. Day, and B.L. Fanburg Rho kinase-induced nuclear translocation of erk1/erk2 in smooth muscle cell mitogenesis caused by serotonin Circ Res 95 2004 579 586
35. R.J. Levy Serotonin transporter mechanisms and cardiac disease Circulation 113 2006 2 4
36. B.I. Gustafsson, K. Tommeras, I. Nordrum, J.P. Loennechen, A. Brunsvik, E. Solligard, R. Fossmark, I. Bakke, U. Syversen, and H. Waldum Long-term serotonin administration induces heart valve disease in rats Circulation 111 2005 1517 1522
37. S. Droogmans, B. Roosens, B. Cosyns, C. Degaillier, S. Hernot, C. Weytjens, C. Garbar, V. Caveliers, M. Pipeleers-Marichal, P.R. Franken, A. Bossuyt, D. Schoors, T. Lahoutte, and G. Van Camp Dose dependency and reversibility of serotonin-induced valvular heart disease in rats Cardiovasc Toxicol 9 2009 134 141
38. R. Zanettini, A. Antonini, G. Gatto, R. Gentile, S. Tesei, and G. Pezzoli Valvular heart disease and the use of dopamine agonists for parkinson's disease N Engl J Med 356 2007 39 46
39. R.B. Rothman, and M.H. Baumann Serotonergic drugs and valvular heart disease Expert Opin Drug Saf 8 2009 317 329
40. C. Hofmann, U. Penner, R. Dorow, H.H. Pertz, S. Jahnichen, R. Horowski, K.P. Latte, D. Palla, and B. Schurad Lisuride, a dopamine receptor agonist with 5-ht2b receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-ht2b receptor agonism in cardiac valvular fibrosis Clin Neuropharmacol 29 2006 80 86
41. R. Schade, F. Andersohn, S. Suissa, W. Haverkamp, and E. Garbe Dopamine agonists and the risk of cardiac-valve regurgitation N Engl J Med 356 2007 29 38
42. L.W. Fitzgerald, T.C. Burn, B.S. Brown, J.P. Patterson, M.H. Corjay, P.A. Valentine, J.H. Sun, J.R. Link, I. Abbaszade, J.M. Hollis, B.L. Largent, P.R. Hartig, G.F. Hollis, P.C. Meunier, A.J. Robichaud, and D.W. Robertson Possible role of valvular serotonin 5-ht(2b) receptors in the cardiopathy associated with fenfluramine Mol Pharmacol 57 2000 75 81
43. R.B. Rothman, M.H. Baumann, J.E. Savage, L. Rauser, A. McBride, S.J. Hufeisen, and B.L. Roth Evidence for possible involvement of 5-ht(2b) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications Circulation 102 2000 2836 2841
44. A. Mekontso-Dessap, F. Brouri, O. Pascal, P. Lechat, N. Hanoun, L. Lanfumey, I. Seif, N. Benhaiem-Sigaux, M. Kirsch, M. Hamon, S. Adnot, and S. Eddahibi Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice Circulation 113 2006 81 89
45. C.S. Elangbam, L.E. Job, L.M. Zadrozny, J.C. Barton, L.W. Yoon, L.D. Gates, and N. Slocum 5-hydroxytryptamine (5ht)-induced valvulopathy: compositional valvular alterations are associated with 5ht2b receptor and 5ht transporter transcript changes in sprague-dawley rats Exp Toxicol Pathol 60 2008 253 262
46. M.A. Oyama, and S.V. Chittur Genomic expression patterns of mitral valve tissues from dogs with degenerative mitral valve disease Am J Vet Res 67 2006 1307 1318
47. S. Disatian, and E.C. Orton Autocrine serotonin and transforming growth factor beta 1 signaling mediates spontaneous myxomatous mitral valve disease J Heart Valve Dis 18 2009 44 51
48. S.M. Scruggs, S. Disatian, and E.C. Orton Serotonin transmembrane transporter is down-regulated in late-stage canine degenerative mitral valve disease J Vet Cardiol 12 2010 163 169
49. M. Hyytiainen, C. Penttinen, and J. Keski-Oja Latent tgf-beta binding proteins: extracellular matrix association and roles in tgf-beta activation Crit Rev Clin Lab Sci 41 2004 233 264
50. R. Khan, and R. Sheppard Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia Immunology 118 2006 10 24
51. K. Yamaguchi, K. Shirakabe, H. Shibuya, K. Irie, I. Oishi, N. Ueno, T. Taniguchi, E. Nishida, and K. Matsumoto Identification of a member of the mapkkk family as a potential mediator of tgf-beta signal transduction Science 270 1995 2008 2011
52. J. Waltenberger, L. Lundin, K. Oberg, E. Wilander, K. Miyazono, C.H. Heldin, and K. Funa Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease Am J Pathol 142 1993 71 78
53. B. Jian, N. Narula, Q.Y. Li, E.R. Mohler 3rd, and R.J. Levy Progression of aortic valve stenosis: Tgf-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis Ann Thorac Surg 75 2003 457 465 discussion 465-456
54. L. Kim, K. Kim do, W.I. Yang, D.H. Shin, I.M. Jung, H.K. Park, and B.C. Chang Overexpression of transforming growth factor-beta 1 in the valvular fibrosis of chronic rheumatic heart disease J Korean Med Sci 23 2008 41 48
55. H. Aupperle, I. Marz, J. Thielebein, and H.A. Schoon Expression of transforming growth factor-beta1, -beta2 and -beta3 in normal and diseased canine mitral valves J Comp Pathol 139 2008 97 107
56. K. Obayashi, S. Miyagawa-Tomita, H. Matsumoto, H. Koyama, T. Nakanishi, and H. Hirose Effects of transforming growth factor-beta3 and matrix metalloproteinase-3 on the pathogenesis of chronic mitral valvular disease in dogs Am J Vet Res 72 2011 194 202
57. G.A. Walker, K.S. Masters, D.N. Shah, K.S. Anseth, and L.A. Leinwand Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease Circ Res 95 2004 253 260
58. W.D. Merryman, H.D. Lukoff, R.A. Long, G.C. Engelmayr Jr., R.A. Hopkins, and M.S. Sacks Synergistic effects of cyclic tension and transforming growth factor-beta1 on the aortic valve myofibroblast Cardiovasc Pathol 16 2007 268 276
59. B. Jian, J. Xu, J. Connolly, R.C. Savani, N. Narula, B. Liang, and R.J. Levy Serotonin mechanisms in heart valve disease i: serotonin-induced up-regulation of transforming growth factor-beta1 via g-protein signal transduction in aortic valve interstitial cells Am J Pathol 161 2002 2111 2121
60. J.S. Grewal, Y.V. Mukhin, M.N. Garnovskaya, J.R. Raymond, and E.L. Greene Serotonin 5-ht2a receptor induces tgf-beta1 expression in mesangial cells via erk: proliferative and fibrotic signals Am J Physiol 276 1999 F922 F930
61. M.D. Combs, and K.E. Yutzey Heart valve development: regulatory networks in development and disease Circ Res 105 2009 408 421
62. R.R. Markwald, and J.T. Butcher The next frontier in cardiovascular developmental biology-an integrated approach to adult disease? Nat Clin Pract Cardiovasc Med 4 2007 60 61
63. R.R. Markwald, R.A. Norris, R. Moreno-Rodriguez, and R.A. Levine Developmental basis of adult cardiovascular diseases: valvular heart diseases Ann N Y Acad Sci 1188 2010 177 183
64. F.C. Caira, S.R. Stock, T.G. Gleason, E.C. McGee, J. Huang, R.O. Bonow, T.C. Spelsberg, P.M. McCarthy, S.H. Rahimtoola, and N.M. Rajamannan Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation J Am Coll Cardiol 47 2006 1707 1712
65. L. Fischer, G. Boland, and R.S. Tuan Wnt-3a enhances bone morphogenetic protein-2-mediated chondrogenesis of murine c3h10t1/2 mesenchymal cells J Biol Chem 277 2002 30870 30878
66. R.S. Tuan Cellular signaling in developmental chondrogenesis: N-cadherin, wnts, and bmp-2 J Bone Jt Surg Am 85-A Suppl. 2 2003 137 141
67. B.S. Yoon, and K.M. Lyons Multiple functions of bmps in chondrogenesis J Cell Biochem 93 2004 93 103
68. H.B. MacLea, R. LCM, J.D. Kisiday, and E.C. Orton Canine and human degenerative mitral valve disease mimic chondrogenesis J Vet Intern Med 25 2011 648
69. C.Y. Logan, and R. Nusse The wnt signaling pathway in development and disease Annu Rev Cell Dev Biol 20 2004 781 810
70. C.E. Macsai, B.K. Foster, and C.J. Xian Roles of wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair J Cell Physiol 215 2008 578 587
71. C. Hartmann, and C.J. Tabin Dual roles of wnt signaling during chondrogenesis in the chicken limb Development 127 2000 3141 3159
72. M.A. Koay, and M.A. Brown Genetic disorders of the lrp5-wnt signalling pathway affecting the skeleton Trends Mol Med 11 2005 129 137
73. V.K. Yadav, and P. Ducy Lrp5 and bone formation: a serotonin-dependent pathway Ann N Y Acad Sci 1192 2010 103 109
74. N.M. Rajamannan Mechanisms of aortic valve calcification: the ldl-density-radius theory: a translation from cell signaling to physiology Am J Physiol Heart Circ Physiol 298 2010 H5 15
75. S. Artavanis-Tsakonas, M.D. Rand, and R.J. Lake Notch signaling: cell fate control and signal integration in development Science 284 1999 770 776
76. L.A. Timmerman, J. Grego-Bessa, A. Raya, E. Bertran, J.M. Perez-Pomares, J. Diez, S. Aranda, S. Palomo, F. McCormick, J.C. Izpisua-Belmonte, and J.L. de la Pompa Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation Genes Dev 18 2004 99 115
77. D. MacGrogan, L. Luna-Zurita, and J.L. de la Pompa Notch signaling in cardiac valve development and disease Birth Defects Res A Clin Mol Teratol 91 2011 449 459
78. V. Garg, A.N. Muth, J.F. Ransom, M.K. Schluterman, R. Barnes, I.N. King, P.D. Grossfeld, and D. Srivastava Mutations in notch1 cause aortic valve disease Nature 437 2005 270 274
79. M. Noris, M. Morigi, R. Donadelli, S. Aiello, M. Foppolo, M. Todeschini, S. Orisio, G. Remuzzi, and A. Remuzzi Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions Circ Res 76 1995 536 543
80. L. Siney, and M.J. Lewis Nitric oxide release from porcine mitral valves Cardiovasc Res 27 1993 1657 1661
81. S.G. Moesgaard, L.H. Olsen, B. Aasted, B.M. Viuff, L.G. Pedersen, H.D. Pedersen, and A.P. Harrison Direct measurements of nitric oxide release in relation to expression of endothelial nitric oxide synthase in isolated porcine mitral valves J Vet Med A Physiol Pathol Clin Med 54 2007 156 160
82. S.G. Moesgaard, L.H. Olsen, B.M. Viuff, U. Baandrup, L.G. Pedersen, P.D. Thomsen, H.D. Pedersen, and A.P. Harrison Increased nitric oxide release and expression of endothelial and inducible nitric oxide synthases in mildly changed porcine mitral valve leaflets J Heart Valve Dis 16 2007 67 75
83. L.H. Olsen, K. Mortensen, T. Martinussen, L.I. Larsson, U. Baandrup, and H.D. Pedersen Increased nadph-diaphorase activity in canine myxomatous mitral valve leaflets J Comp Pathol 129 2003 120 130
84. S. Hafizi, P.M. Taylor, A.H. Chester, S.P. Allen, and M.H. Yacoub Mitogenic and secretory responses of human valve interstitial cells to vasoactive agents J Heart Valve Dis 9 2000 454 458
85. T. Mow, K. Poulsen, A.H. Nielsen, U. Baandrup, B.F. Hansen, and H.D. Pedersen Species differences in expression of angiotensin ii receptors and angiotensin-converting enzyme in human, canine and rat mitral valve leaflets Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 124 1999 11 17
86. T. Mow, and H.D. Pedersen No expression of angiotensin ii receptors and angiotensin-converting enzyme in myxomatous canine mitral valve leaflets. An autoradiographic study Zentralbl Veterinarmed A 46 1999 465 472
87. C. Kupfahl, D. Pink, K. Friedrich, H.R. Zurbrugg, M. Neuss, C. Warnecke, J. Fielitz, K. Graf, E. Fleck, and V. Regitz-Zagrosek Angiotensin ii directly increases transforming growth factor beta1 and osteopontin and indirectly affects collagen mrna expression in the human heart Cardiovasc Res 46 2000 463 475
88. NIH-NHLBI Division of cardiovascular diseases strategic plan 2007 http://www.Nhlbi.Nih.Gov/about/dcvd/sp/dcvd-sp-goal-2.1d.Htm